Andere Sprachen Cyxone AB

Aktien

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 18:00:00 28.06.2024			% 5 Tage	% 1. Jan.
0,11 ^SEK	0,00 %		-16,67 %	+9,56 %

14.05.	Cyxone AB (publ) meldet Ergebniszahlen für das erste Quartal zum 31. März 2024	CI
22.04.	Cyxone AB (publ) gibt Änderungen im Vorstand bekannt	CI

Cyxone AB Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Sweden's Cyxone Appoints New CEO	22.04.
Kjell Stenberg new CEO in Cyxone AB	22.04.
Cyxone AB Announces Chief Executive Officer Changes	22.04.
BioStock: Cyxone comments on the clinical collaboration in the UK	28.03.
Cyxone Enters Research Deal for Rheumatoid Arthritis Therapy	25.03.
Cyxone enters important research collaboration	25.03.
Cyxone Enters Important Research Collaboration with University of Glasgow	25.03.
BioStock: Cyxone's CEO gives a status update	05.03.
Cyxone AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27.02.
BioStock: Cyxone identifies target protein for rabeximod	17.01.
Cyxone reaches important milestone regarding mechanism of action	15.01.
Cyxone Reaches an Important Milestone for the Drug Candidate Rabeximod	15.01.
Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor	20.11.
Interim Report 1 January to 30 September 2023	27.10.23
Cyxone AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27.10.23
Cyxone to Receive Unitary Patent in EU for T20K Drug Candidate	09.10.23
Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K	09.10.23
BioStock Investor Meeting: Cyxone	27.09.23
Interim Report 1 January to 30 June 2023	30.08.23

Keine Ergebnisse zu dieser Suche